FR2422164A1 - Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant - Google Patents

Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant

Info

Publication number
FR2422164A1
FR2422164A1 FR7800321A FR7800321A FR2422164A1 FR 2422164 A1 FR2422164 A1 FR 2422164A1 FR 7800321 A FR7800321 A FR 7800321A FR 7800321 A FR7800321 A FR 7800321A FR 2422164 A1 FR2422164 A1 FR 2422164A1
Authority
FR
France
Prior art keywords
heparin
blood
thrombin
reaction
concn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7800321A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNERFIELD H
Original Assignee
INNERFIELD H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNERFIELD H filed Critical INNERFIELD H
Priority to FR7800321A priority Critical patent/FR2422164A1/en
Publication of FR2422164A1 publication Critical patent/FR2422164A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Blood heparin concns. in heparinised patients are determined by adding serum from the blood to standardised thrombin soln. and incubating the mixt. at a selected temp. for a defined period (too short for reaction between thrombin and any fibrin degradation prod. but sufficient for reaction between thrombin and heparin). A standard portion of the mixture is then added to normal plasma that has been equilibrated at the same selected temp. The clotting time of the resulting mixture is observed; it is an inverse function of the amt. of thrombin left after reaction with heparin and is a direct function of blood heparin. The clotting time is compared with standard curves prepd. by using serum from healthy individuals to whch standard amts. of heparin had been added. Rapid, sensitive and reliable method for determining heparin in blood to give accurate monitoring when heparin is used as an anticoagulant. The relationship between heparin content and the concn. of antithrombin III can be drawn.
FR7800321A 1978-01-06 1978-01-06 Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant Withdrawn FR2422164A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7800321A FR2422164A1 (en) 1978-01-06 1978-01-06 Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7800321A FR2422164A1 (en) 1978-01-06 1978-01-06 Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant

Publications (1)

Publication Number Publication Date
FR2422164A1 true FR2422164A1 (en) 1979-11-02

Family

ID=9203183

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7800321A Withdrawn FR2422164A1 (en) 1978-01-06 1978-01-06 Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant

Country Status (1)

Country Link
FR (1) FR2422164A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853710A (en) * 1973-01-15 1974-12-10 Ass For Pharmacologic Res Inc Serum diagnostic test for maladies causing change in fibrinolytic activity in the blood
FR2309194A1 (en) * 1975-05-02 1976-11-26 Innerfield Irving METHOD FOR DETECTION OF THROMBOSIS AND PRETHROMBOSIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853710A (en) * 1973-01-15 1974-12-10 Ass For Pharmacologic Res Inc Serum diagnostic test for maladies causing change in fibrinolytic activity in the blood
FR2309194A1 (en) * 1975-05-02 1976-11-26 Innerfield Irving METHOD FOR DETECTION OF THROMBOSIS AND PRETHROMBOSIS

Similar Documents

Publication Publication Date Title
EP0420332A3 (en) Method for determining the endogenous thrombin potential of plasma and blood, and also a kit or use in said method
Lippi et al. Activated partial thromboplastin time: new tricks for an old dogma
AU591465B2 (en) Methods for coagulation monitoring
Nsiri et al. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease
ES2088992T3 (en) METHOD TO DETERMINE THE LEVELS OF INTRINSIC AND EXTRINSIC COAGULATION FACTORS AND PROTEIN C.
Lindhoff-Last et al. Hirudin Determination in Plasma Can Be Strongly Influenced by the Prothrombin Level☆
EP0632270A4 (en) Method of assaying activity of blood coagulation factor xiii and reagent kit therefor.
DE59813326D1 (en) Method for determining the anticoagulant potential of a sample and method for determining the glycosylation of thrombomodulin
IE42546L (en) Method of measuring serum coagulability
Bounameaux et al. Monitoring of Heparin Treatment. Comparison between Thrombin Time, Activated Partial Thromboplastin Time, and Plasma Heparin Concentration, and Analysis of the Behavior of Antithrombin III.
AU1538202A (en) A reagent and kit for determining global coagulability and hemostatic potential
ES455030A1 (en) Quantitative determination of antithrombin III
Roussi et al. Contribution of D-Dimer determination in the exclusion of deep venous thrombosis in spinal cord injury patients
Sturk et al. Analytical and clinical evaluation of commercial protein C assays
FR2422164A1 (en) Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant
NL7713422A (en) Determination of blood heparin concn. - by rapid, sensitive and accurate method using heparin as anticoagulant
Erskine et al. Maintenance control of oral anticoagulant therapy by a chromogenic substrate assay for factor X.
Nilsson et al. Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant
DK0626070T3 (en) Method for Determination of Hirudin and Synthetic Thrombin Inhibitors
Shen et al. Differential activities of heparins in human plasma and in sheep plasma. Effects of heparin molecular sizes and sources
Pabinger et al. Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays
Takahashi et al. Fast functional assay of protein C in whole plasma using a snake venom activator: evaluation in patients with congenital and acquired protein C deficiencies
DE69916816D1 (en) IMPROVED BLOOD CLUTTER TEST
DE59205827D1 (en) Method for determining fibrin
Vukovich et al. Quantitative determination of human protein C evaluation of a “fast” functional assay in comparison to a “traditional” functional and an immunological assay

Legal Events

Date Code Title Description
ST Notification of lapse